Experts warn that focus on GLP‑1 weight‑loss drugs may threaten insulin availability
The head of the Access to Medicine Foundation cautions that the pharmaceutical industry's emphasis on GLP‑1 products such as Ozempic and Mounjaro could divert attention from diabetes treatments like insulin, potentially…